LY2409881 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as an inhibitor of the IKK2 enzyme, which plays a critical role in the NF-κB signaling pathway. By targeting this pathway, LY2409881 may help reduce inflammation and inhibit tumor growth, making it a candidate for treating cancers where NF-κB is overly active. Research has focused on its efficacy in preclinical models of various cancers, including breast and prostate cancer, to assess its ability to suppress tumor progression and enhance the effects of other anticancer therapies. Its application is still largely experimental, with ongoing studies aimed at understanding its full potential and safety profile in clinical settings.